Brief: Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab In Phase 2 Multiple Sclerosis Clinical Trial
02/04/2025 13:08
April 2 (Reuters) - Tiziana Life Sciences Ltd TLSA.O: TIZIANA LIFE SCIENCES ANNOUNCES JOHNS HOPKINS UNIVERSITY COMMENCES DOSING NASAL FORALUMAB IN PHASE 2 MULTIPLE SCLEROSIS CLINICAL TRIAL Source text: ID:nGNX5Lwr9l Further company coverage: TLSA.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Tiziana Life Sciences
See all newsTiziana's experimental MS treatment meets main goals in mid-stage study
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis